Tenderwize
Retour à la recherche

Epinephrine (ATC C01CA24)

AOK - Die Gesundheitskasse in Hessen·Bad Homburg, Germany·Deadline Dec 01, 2026 · 47 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V (Open-House-Modell)

38/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

38 / 100

Complexité

42 / 100

Facteurs de risque

Structured data says electronic submission is not allowed, while the XML notice text says prior electronic submission b...

The XML notice text states that the Epinephrin procedure is withdrawn/terminated on 28.02.2026, which may affect whethe...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Informations clés

Pouvoir adjudicateur
AOK - Die Gesundheitskasse in Hessen
Pays
Allemagne
CPV
33600000 - Pharmaceutical products
Date limite
Dec 01, 2026

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Jan 2027
  • Conclusion of non-exclusive rebate agreements under §130a(8) SGB V for finished medicinal products with various active substances or combinations.
  • Open-house model: accession/contract conclusion possible at any time under identical conditions.
Afficher le résumé complet

This is an open-house notice for non-exclusive rebate agreements under §130a(8) SGB V for pharmaceutical products (CPV 33600000) in Germany, led by AOK - Die Gesundheitskasse in Hessen. The notice states that accession/contract conclusion is possible at any time on the same conditions, with no individual negotiations. One lot is explicitly identified: Epinephrin (ATC C01CA24), but the lot is also stated to be withdrawn/terminated on 28.02.2026. No contract value is provided. Electronic submission is not allowed; the XML text indicates prior email submission to the buyer contact, which is an inconsistency to note.

Risques

Structured data says electronic submission is not allowed, while the XML notice text says prior electronic submission b...

The XML notice text states that the Epinephrin procedure is withdrawn/terminated on 28.02.2026, which may affect whethe...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Administrative

  • Submission language is German.
  • Electronic submission is not allowed according to structured data.
  • The XML notice states prior electronic submission by email to [email protected], which conflicts with the structured electronicSubmission flag.

Acheteur

Localisation

Bad Homburg, DEU

Site web

www.aok.de

Identifiant

DE114110216

Activité

Health

Lots (1)

LOT-0003

Epinephrine (ATC C01CA24)

Open-house rebate agreement for the active substance Epinephrin. The lot is explicitly stated in the XML notice text as being withdrawn/terminated on 28.02.2026, despite also showing a start date of 01.02.2025 and an end date of 31.01.2027 in the structured data. Source: structured data and XML notice text.

SuppliesEU fundedElectronic submission

Localisation

Germany

Durée

Jan 2025 - Jan 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Dec 01, 2026

Détails de la procédure

Date de publication
22 Jan 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
51271-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.

Dec 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30